Europe Multiple Myeloma Therapeutics Market is at the cusp of crossing USD 2.00 billion in 2022
Multiple Myeloma Therapeutics Market, published by Market Data Forecast, the Europe market was worth USD 1.88 billion in 2017 and estimated to be growing at a CAGR of 4.58%, to reach USD 2.35 billion by 2022.
(EMAILWIRE.COM, December 16, 2017 ) Multiple Myeloma is an affliction of kidney which also affects bone and blood cells. Loss of appetite, severe fatigue, increased urination and pain in the bones are its most common symptoms. A combination of urine tests, bone marrow tests, and several blood tests are required to ascertain the presence of this disease. Men are more likely to contract Multiple Myeloma market as compared to women and the chances increase as one grows older.
Get a comprehensive overview of the Multiple Myeloma Therapeutics Market: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Multiple Myeloma Therapeutics Market: Drivers & Restraints
Factors such as augmenting geriatric population in the European countries coupled with rising number of cases of chronic diseases are some of the main hinderances to the market growth in this region.
Several cases of patient health deterioration after treatment and ripen treatment resistance have been reported which is the primary restraint of this market.
Get accurate market forecast and analysis on the Multiple Myeloma Therapeutics Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
Multiple Myeloma Therapeutics Market: Segmentation
By Treatment Type
• Chemotherapy
o Anthracycline Antibiotic
o Alkylating agent
• Targeted Therapy
o Proteasome inhibitor
By Drug Type
• Corticosteroids
o Dexamethasone (Decadron)
o Prednisone (Deltasone/Orasone)
• Immunomodulatory agents
o Thalidomide (Thalomid)
o Lenalidomide (Revlimid)
o Arsenic trioxide (Trisenox)
o Plerixafor (Mozobil)
By Geography
• Europe
o U.K
o Spain
o Germany
o Italy
o France
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization.
Get customization at http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/customize-report/
Multiple Myeloma Therapeutics Market: Overview
In 2017, by treatment type Chemotherapy was the market leader and is predicted to maintain its lead in the aforementioned forecast period. Lack of alternatives and limited surgical procedures are the factors attributable to the observable trend mentioned above. If we go by drug type than Immunomodulation agent lead the market. However, monoclonal antibodies segment is predicted to grow with the highest CAGR in the aforementioned forecast period.
As 0f 2017, Europe accounted for the second largest share of the Multiple Myeloma Therapeutics Market in the aforementioned forecast period. Presence of a lot of companies, easy adoption of newer treatment options are the factors attributable to the observable trend mentioned above.
Multiple Myeloma Therapeutics Market: Key Players
Some of the major companies competing in the Multiple Myeloma Therapeutics are MAB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC., ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
Get a comprehensive overview of the Multiple Myeloma Therapeutics Market: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/
Multiple Myeloma Therapeutics Market: Drivers & Restraints
Factors such as augmenting geriatric population in the European countries coupled with rising number of cases of chronic diseases are some of the main hinderances to the market growth in this region.
Several cases of patient health deterioration after treatment and ripen treatment resistance have been reported which is the primary restraint of this market.
Get accurate market forecast and analysis on the Multiple Myeloma Therapeutics Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/request-sample
Multiple Myeloma Therapeutics Market: Segmentation
By Treatment Type
• Chemotherapy
o Anthracycline Antibiotic
o Alkylating agent
• Targeted Therapy
o Proteasome inhibitor
By Drug Type
• Corticosteroids
o Dexamethasone (Decadron)
o Prednisone (Deltasone/Orasone)
• Immunomodulatory agents
o Thalidomide (Thalomid)
o Lenalidomide (Revlimid)
o Arsenic trioxide (Trisenox)
o Plerixafor (Mozobil)
By Geography
• Europe
o U.K
o Spain
o Germany
o Italy
o France
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization.
Get customization at http://www.marketdataforecast.com/market-reports/europe-multiple-myeloma-therapeutics-market-860/customize-report/
Multiple Myeloma Therapeutics Market: Overview
In 2017, by treatment type Chemotherapy was the market leader and is predicted to maintain its lead in the aforementioned forecast period. Lack of alternatives and limited surgical procedures are the factors attributable to the observable trend mentioned above. If we go by drug type than Immunomodulation agent lead the market. However, monoclonal antibodies segment is predicted to grow with the highest CAGR in the aforementioned forecast period.
As 0f 2017, Europe accounted for the second largest share of the Multiple Myeloma Therapeutics Market in the aforementioned forecast period. Presence of a lot of companies, easy adoption of newer treatment options are the factors attributable to the observable trend mentioned above.
Multiple Myeloma Therapeutics Market: Key Players
Some of the major companies competing in the Multiple Myeloma Therapeutics are MAB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC., ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results